In part 1 of a two-part podcast, Dr Mease reviews the findings of two clinical trials of the TYK 2 inhibitor deucravacitinib: POETYK 1 of patients without previous biologic treatment, POETYK 2, which included some patients with exposure to...
In part 1 of a two-part podcast, Dr Mease reviews the findings of two clinical trials of the TYK 2 inhibitor deucravacitinib: POETYK 1 of patients without previous biologic treatment, POETYK 2, which included some patients with exposure to...
In part 2 of her video on psoriatic arthritis and obesity, Dr Ogdie reviews recent studies showing how combination therapy with GLP-1 RAs may not only boost weight loss but also help patients achieve minimal disease activity.
In part 2 of her video on psoriatic arthritis and obesity, Dr Ogdie reviews recent studies showing how combination therapy with GLP-1 RAs may not only boost weight loss but also help patients achieve minimal disease activity.
In the first of two videos on the impact and treatment of obesity in psoriatic arthritis, Dr Alexis Ogdie reviews recent research on how obesity affects the severity of disease and the effect of weight loss on patients with PsA.
In the first of two videos on the impact and treatment of obesity in psoriatic arthritis, Dr Alexis Ogdie reviews recent research on how obesity affects the severity of disease and the effect of weight loss on patients with PsA.
The European Alliance of Associations for Rheumatology (EULAR) updated its 2019 guideline for the management of psoriatic arthritis to integrate new data and therapies.
The European Alliance of Associations for Rheumatology (EULAR) updated its 2019 guideline for the management of psoriatic arthritis to integrate new data and therapies.
A first biologic disease-modifying antirheumatic drug showed similar efficacy among psoriatic arthritis patients with a low number of affected joints as among those with a high number.
A first biologic disease-modifying antirheumatic drug showed similar efficacy among psoriatic arthritis patients with a low number of affected joints as among those with a high number.
